245 related articles for article (PubMed ID: 29218366)
1. Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells.
Bachanova V; Sarhan D; DeFor TE; Cooley S; Panoskaltsis-Mortari A; Blazar BR; Curtsinger JM; Burns L; Weisdorf DJ; Miller JS
Cancer Immunol Immunother; 2018 Mar; 67(3):483-494. PubMed ID: 29218366
[TBL] [Abstract][Full Text] [Related]
2. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
[TBL] [Abstract][Full Text] [Related]
3. Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.
Shaffer BC; Le Luduec JB; Forlenza C; Jakubowski AA; Perales MA; Young JW; Hsu KC
Biol Blood Marrow Transplant; 2016 Apr; 22(4):705-709. PubMed ID: 26772158
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic natural killer cells for refractory lymphoma.
Bachanova V; Burns LJ; McKenna DH; Curtsinger J; Panoskaltsis-Mortari A; Lindgren BR; Cooley S; Weisdorf D; Miller JS
Cancer Immunol Immunother; 2010 Nov; 59(11):1739-44. PubMed ID: 20680271
[TBL] [Abstract][Full Text] [Related]
5. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients.
Curti A; Ruggeri L; D'Addio A; Bontadini A; Dan E; Motta MR; Trabanelli S; Giudice V; Urbani E; Martinelli G; Paolini S; Fruet F; Isidori A; Parisi S; Bandini G; Baccarani M; Velardi A; Lemoli RM
Blood; 2011 Sep; 118(12):3273-9. PubMed ID: 21791425
[TBL] [Abstract][Full Text] [Related]
6. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.
Liu E; Marin D; Banerjee P; Macapinlac HA; Thompson P; Basar R; Nassif Kerbauy L; Overman B; Thall P; Kaplan M; Nandivada V; Kaur I; Nunez Cortes A; Cao K; Daher M; Hosing C; Cohen EN; Kebriaei P; Mehta R; Neelapu S; Nieto Y; Wang M; Wierda W; Keating M; Champlin R; Shpall EJ; Rezvani K
N Engl J Med; 2020 Feb; 382(6):545-553. PubMed ID: 32023374
[TBL] [Abstract][Full Text] [Related]
7. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study.
Choi I; Yoon SR; Park SY; Kim H; Jung SJ; Jang YJ; Kang M; Yeom YI; Lee JL; Kim DY; Lee YS; Kang YA; Jeon M; Seol M; Lee JH; Lee JH; Kim HJ; Yun SC; Lee KH
Biol Blood Marrow Transplant; 2014 May; 20(5):696-704. PubMed ID: 24525278
[TBL] [Abstract][Full Text] [Related]
8. CD56-enriched donor cell infusion after post-transplantation cyclophosphamide for haploidentical transplantation of advanced myeloid malignancies is associated with prompt reconstitution of mature natural killer cells and regulatory T cells with reduced incidence of acute graft versus host disease: A pilot study.
Jaiswal SR; Zaman S; Nedunchezhian M; Chakrabarti A; Bhakuni P; Ahmed M; Sharma K; Rawat S; O'donnell P; Chakrabarti S
Cytotherapy; 2017 Apr; 19(4):531-542. PubMed ID: 28131632
[TBL] [Abstract][Full Text] [Related]
9. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.
Bachanova V; Cooley S; Defor TE; Verneris MR; Zhang B; McKenna DH; Curtsinger J; Panoskaltsis-Mortari A; Lewis D; Hippen K; McGlave P; Weisdorf DJ; Blazar BR; Miller JS
Blood; 2014 Jun; 123(25):3855-63. PubMed ID: 24719405
[TBL] [Abstract][Full Text] [Related]
10. Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML.
Björklund AT; Carlsten M; Sohlberg E; Liu LL; Clancy T; Karimi M; Cooley S; Miller JS; Klimkowska M; Schaffer M; Watz E; Wikström K; Blomberg P; Wahlin BE; Palma M; Hansson L; Ljungman P; Hellström-Lindberg E; Ljunggren HG; Malmberg KJ
Clin Cancer Res; 2018 Apr; 24(8):1834-1844. PubMed ID: 29444931
[No Abstract] [Full Text] [Related]
11. Cytotoxicity of Donor Natural Killer Cells to Allo-Reactive T Cells Are Related With Acute Graft-vs.-Host-Disease Following Allogeneic Stem Cell Transplantation.
Sheng L; Mu Q; Wu X; Yang S; Zhu H; Wang J; Lai Y; Wu H; Sun Y; Hu Y; Fu H; Wang Y; Xu K; Sun Y; Zhang Y; Zhang P; Zhou M; Lai B; Xu Z; Gao M; Zhang Y; Ouyang G
Front Immunol; 2020; 11():1534. PubMed ID: 32849519
[No Abstract] [Full Text] [Related]
12. First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia.
Cooley S; He F; Bachanova V; Vercellotti GM; DeFor TE; Curtsinger JM; Robertson P; Grzywacz B; Conlon KC; Waldmann TA; McKenna DH; Blazar BR; Weisdorf DJ; Miller JS
Blood Adv; 2019 Jul; 3(13):1970-1980. PubMed ID: 31266741
[TBL] [Abstract][Full Text] [Related]
13. Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy.
Berrien-Elliott MM; Becker-Hapak M; Cashen AF; Jacobs M; Wong P; Foster M; McClain E; Desai S; Pence P; Cooley S; Brunstein C; Gao F; Abboud CN; Uy GL; Westervelt P; Jacoby MA; Pusic I; Stockerl-Goldstein KE; Schroeder MA; DiPersio JF; Soon-Shiong P; Miller JS; Fehniger TA
Blood; 2022 Feb; 139(8):1177-1183. PubMed ID: 34797911
[TBL] [Abstract][Full Text] [Related]
14. A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia.
Fehniger TA; Miller JS; Stuart RK; Cooley S; Salhotra A; Curtsinger J; Westervelt P; DiPersio JF; Hillman TM; Silver N; Szarek M; Gorelik L; Lowdell MW; Rowinsky E
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1581-1589. PubMed ID: 29597002
[TBL] [Abstract][Full Text] [Related]
15. Phase I Study: Safety and Efficacy of an Ex Vivo-Expanded Allogeneic Natural Killer Cell (MG4101) with Rituximab for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma.
Yoon DH; Koh Y; Jung M; Kwak JE; Shin EC; Hwang YK; Kim WS
Transplant Cell Ther; 2023 Apr; 29(4):253.e1-253.e9. PubMed ID: 36610490
[TBL] [Abstract][Full Text] [Related]
16. Adoptive immunotherapy with double-bright (CD56
Silla L; Valim V; Pezzi A; da Silva M; Wilke I; Nobrega J; Vargas A; Amorin B; Correa B; Zambonato B; Scherer F; Merzoni J; Sekine L; Huls H; Cooper LJ; Paz A; Lee DA
Br J Haematol; 2021 Dec; 195(5):710-721. PubMed ID: 34490616
[TBL] [Abstract][Full Text] [Related]
17. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation.
Shi J; Tricot G; Szmania S; Rosen N; Garg TK; Malaviarachchi PA; Moreno A; Dupont B; Hsu KC; Baxter-Lowe LA; Cottler-Fox M; Shaughnessy JD; Barlogie B; van Rhee F
Br J Haematol; 2008 Dec; 143(5):641-53. PubMed ID: 18950462
[TBL] [Abstract][Full Text] [Related]
18. Donor-Derived Natural Killer Cell Infusion after Human Leukocyte Antigen-Haploidentical Hematopoietic Cell Transplantation in Patients with Refractory Acute Leukemia.
Choi I; Yoon SR; Park SY; Kim H; Jung SJ; Kang YL; Lee JH; Lee JH; Kim DY; Lee JL; Park HS; Choi EJ; Lee YS; Kang YA; Jeon M; Seol M; Baek S; Yun SC; Kim HJ; Lee KH
Biol Blood Marrow Transplant; 2016 Nov; 22(11):2065-2076. PubMed ID: 27530969
[TBL] [Abstract][Full Text] [Related]
19. Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant.
Bednarski JJ; Zimmerman C; Berrien-Elliott MM; Foltz JA; Becker-Hapak M; Neal CC; Foster M; Schappe T; McClain E; Pence PP; Desai S; Kersting-Schadek S; Wong P; Russler-Germain DA; Fisk B; Lie WR; Eisele J; Hyde S; Bhatt ST; Griffith OL; Griffith M; Petti AA; Cashen AF; Fehniger TA
Blood; 2022 Mar; 139(11):1670-1683. PubMed ID: 34871371
[TBL] [Abstract][Full Text] [Related]
20. Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells.
Guolo F; Minetto P; Pesce S; Ballerini F; Clavio M; Cea M; Frello M; Garibotto M; Greppi M; Bozzo M; Miglino M; Passannante M; Marcolin R; Tedone E; Colombo N; Mangerini R; Bo A; Ruzzenenti MR; Carlier P; Serio A; Luchetti S; Dominietto A; Varaldo R; Candiani S; Agostini V; Ravetti JL; Del Zotto G; Marcenaro E; Lemoli RM
Front Immunol; 2021; 12():753890. PubMed ID: 34804039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
